FINWIRES · TerminalLIVE
FINWIRES

研究快讯:IBM:业绩超预期,但软件增速放缓抵消了咨询业务的韧性

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下: 2026年第一季度业绩略超预期,销售额达159亿美元(同比增长9%),非GAAP每股收益为1.91美元(同比增长19%),分别高于市场普遍预期的157亿美元和1.81美元。按固定汇率计算,销售额增长6%,较前两个季度的9%和7%有所放缓,但管理层维持了2026年按固定汇率计算的收入增长“超过5%”和自由现金流约为157亿美元的预期。软件业务按固定汇率计算的增长从第四季度的11%和第三季度的9%放缓至8%,这可能对空头构成潜在风险信号,尽管红帽业务的增长从第四季度的8%反弹至10%。因此,我们预计近期持续约20%的订单增长将支撑今年两位数左右的销售额增长。基础设施业务保持强劲增长,按固定汇率计算增长12%,IBM Z系列产品销售额同比增长51%,但未来增长将面临更大的基数压力。我们认为IBM营业利润率同比增长110个基点令人印象深刻,而咨询业务的韧性(销售额增长1%,签约量增长10%)至少在目前应该能够缓解人们对Anthropic相关COBOL竞争的担忧。

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF